PF-07985631 / Pfizer - LARVOL DELTA

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Pfizer | N=76 ➔ 9 | Trial completion date: Aug 2027 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2027 ➔ Jul 2026; The estimated benefit-risk profile of PF-07985631 is not anticipated to be favorable in the expected population to be treated

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion acquisition of Metsera. (FierceBiotech) - "The oral, fully biased, ultra-long-acting GLP-1 drug, dubbed MET-224o, was one of the rewards from Pfizer's successful resolution of the bidding war with Novo Nordisk last year to secure Metsera....The other, called MET-097o, was an oral formulation...The other clinical-stage obesity prospect to be scrapped by Pfizer this morning is PF-07976016...They included PF-07258669, an MC4R antagonist for malnutrition that had already seen its phase 1 study cut short earlier this year for business reasons....The last of Pfizer's abandoned assets was PF-07985631, which was in phase 1 development for nephropathy."

Discontinued • Cachexia • Obesity • Renal Disease

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults (clinicaltrials.gov) - P1 | N=92 | Recruiting | Sponsor: Pfizer | Active, not recruiting ➔ Recruiting

Enrollment open • Trial initiation date